CD47 and thrombospondin-1 regulation of mitochondria, metabolism, and diabetes

Thrombospondin-1 (TSP1) is the prototypical member of a family of secreted proteins that modulate cell behavior by engaging with molecules in the extracellular matrix and with receptors on the cell surface. CD47 is widely displayed on many, if not all, cell types and is a high-affinity TSP1 receptor. CD47 is a marker of self that limits innate immune cell activities, a feature recently exploited to enhance cancer immunotherapy. Another major role for CD47 in health and disease is to mediate TSP1 signaling. TSP1 acting through CD47 contributes to mitochondrial, metabolic, and endocrine dysfunction. Studies in animal models found that elevated TSP1 expression, acting in part through CD47, causes mitochondrial and metabolic dysfunction. Clinical studies established that abnormal TSP1 expression positively correlates with obesity, fatty liver disease, and diabetes. The unabated increase in these conditions worldwide and the availability of CD47 targeting drugs justify a closer look into how TSP1 and CD47 disrupt metabolic balance and the potential for therapeutic intervention.

Automated summary

Thrombospondin-1 (TSP1) is a family of secreted proteins that modulate cell behavior by interacting with molecules in the extracellular matrix and cell surface receptors, with CD47 being a high-affinity receptor for TSP1. CD47 is crucial in limiting innate immune cell activities and mediating TSP1 signaling, contributing to mitochondrial, metabolic, and endocrine dysfunction. Elevated TSP1 expression, particularly through CD47, is associated with obesity, fatty liver disease, and diabetes, suggesting a potential for therapeutic intervention.